Biohaven skunked by a placebo in PhII/III flop for ataxia drug, shares slide
Biohaven $BHVN helped prove just how fast you could assemble a pipeline and a successful biotech IPO this year. And now it has shown just …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
